Hi there!
We track 70,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
Archon Biosciences
Archon Biosciences develops a new class of biologic drugs that combine antibody specificity with engineered nanostructures to target disease more precisely. The company applies generative protein…
Archon Biosciences
Archon Biosciences develops a new class of biologic drugs that combine antibody specificity with engineered nanostructures to target disease more precisely. The company applies generative protein…
TL;DR
Founded: 2023
Headquarters: Seattle (evidence: company described as Seattle-based)
Technology: Antibody Cages (computationally designed, self-assembling antibody-integrated nanostructures)
Seed funding: $20M seed (announced Oct 30, 2024)
Leadership: James Lazarovits, Ph.D. (CEO); George Ueda, Ph.D. (CTO)
Company Overview
Problem Domain
Biologic therapeutics for challenging targets requiring controlled geometry and biodistribution.
Founded
2023
Industry
Biotechnology
Funding Track Record
$20,000,000
Participating investors named: DUMAC Inc., Sahsen Ventures, WRF Capital, Pack Ventures, Alexandria Venture Investments, Cornucopian Capital
Investor Signal
“Madrona partners hold board/observer roles (board member: Chris Picardo; board observer: Matt McIlwain) reflecting lead investor engagement”
Founders
What we do
Join the Team
Startup jobs. A lot of them.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,500+
New This Week